LyGenesis has developed a new experimental medicine that grows miniature livers within patients’ lymph nodes, presenting a ground-breaking approach to medical treatment. This therapy, called LYG-LIV-001, involves transferring hepatocytes from donor livers into the recipient’s lymph nodes, where they are expected to grow into fully functional liver tissue.
This medication, which primarily targets end-stage liver disease (ESLD), has the potential to alleviate the current scarcity of organ donors, resulting to major advances in patient care and saving many lives. Although the trial’s conclusion is unknown, LyGenesis sees broader uses for this technique, such as producing tissues for the kidneys, thymus, and pancreas, paving the door for revolutionary advances in the field of regeneration medicine.
